Hemorheological changes in solid tumor patients after treatment with recombinant erythropoetine

Clinical Hemorheology and Microcirculation

Volumn 41, Issue 1, 2009, Pages 39-47

  Muravyov, A V ^a   Cheporov, S V ^a   Kislov, N V ^a   Volkova, E L ^a  

^a YAROSLAVL STATE PEDAGOGICAL UNIVERSITY   (Russian Federation)

Author keywords

Aggregation; Anemia; Deformation; Erythropoetine; Hemorheological profile; Red blood cells; Solid tumors

Indexed keywords

CALCIUM; CISPLATIN; CLOTRIMAZOLE; HEMOGLOBIN; HEPARIN; PHOSPHATASE; PROTEIN TYROSINE KINASE; RECOMBINANT ERYTHROPOIETIN; VANADIC ACID; VERAPAMIL;

ADULT; ANEMIA; ARTICLE; BLOOD RHEOLOGY; BLOOD SAMPLING; BLOOD VISCOSITY; CALCIUM TRANSPORT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ERYTHROCYTE; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTE MEMBRANE; FEMALE; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HUMAN; MALE; PILOT STUDY; PLASMA; SHEAR STRESS; SIGNAL TRANSDUCTION; SOLID TUMOR;

AGED; ANEMIA; CASE-CONTROL STUDIES; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 58149380033     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: 10.3233/CH-2009-1153     Document Type: Article

References (32)

1. H.F. Bunn and R.O. Poyton, Oxygen sensing and molecular adaptation to hypoxia, Am. Physiol. Rev. 76 (1996), 839-885.
2. R. Berardi, C. Braconi, G. Mantello et al., Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer, Ann. Oncol. 12 (2006), 1221-1224.
3. C.A. Hudis, C.L. Vogel, J.R. Gralow and D. Williams, Procrit Study Group. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life, Clin. Breast Cancer 6 (2005), 132-142.
4. C. Granetto, S. Ricci, A. Martoni et al., Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alfa in anemic cancer patients receiving platinum- based chemotherapy, Oncol. Rep. 10(5) (2003), 1289-1296.
5. M.R. Nowrousian, Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours, Med. Oncol. 15 (1998), S19-S28.
6. A.O. Mancuso, M. Di Molfetta, D.F. Beccaglia and E. Cortesi, A new induction schedule of epoetin alfa 40,000 IU in anemic patients with advanced lung cancer, Lung Cancer 46 (2004), 119-124.
7. J. Glaspy and Y. Beguin, Anaemia management strategies: optimizing treatment using epoetin beta (NeoRecormon), Oncology 69 (2005), 8-16.
8. D. Santini, B. Vincenzi, A. La Cesa et al., A new dose-intense epoetin Alfa regimen effective in anemic cancer patients receiving chemotherapy: an open label, non randomized, pilot study, Anticancer Res. 25 (2005), 669-674.
9. J. Patton, M. Kuzur,W. Liggetti et at., Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy, Oncologist 9 (2004), 90-96.
10. J.F. Stoltz,M. Donner, S. Muller and A. Larcan, Hemorheology in clinical practice. Introduction to the notion of hemorheologic profile, J. Mal. Vasc. 6 (1991), 261-270.
11. L. Dintenfass, Blood Viscosity, Hyperviscosity and Hyperviscosaemia, MTP Press, Melbourne, 1986.
12. A.V. Muravyov, V.V. Yakusevich, F.A. Chuchkanov et al., Hemorheological efficiency of drugs, targeting on intracellular phosphodiesterase activity: In vitro study, Clin. Hemorheol. Microcirc. 36 (2007), 327-334.
13. N. Voravud and V. Sriuranpong, Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy, J. Med. Assoc. Thai. 88 (2005), 607-612.
14. G. Késmárky, P. Kenyeres, M. Rábai and K. Tóth, Plasma viscosity: A forgotten variable, Clin. Hemorheol. Microcirc. 39 (2008), 243-246.
15. G.F. von Tempelhoff, N. Schönmann, L. Heilmann, K. Pollow and G. Hommel, Prognostic role of plasma viscosity in breast cancer, Clin. Hemorheol. Microcirc. 26 (2002), N1, 55-61.
16. O.K. Baskurt et al. (eds), Handbook of Hemorheology and Hemodynamics, IOS Press, Amsterdam, 2007, pp. 392-432.
17. P. Johnson, M. Cabel and A. Popel, Venous resistance and red cell aggregation, in: Abstr. Microcirculatory Soc. 41st Annu. Conf., Anaheim, CA, 1994, pp. 82-83.
18. J.J. Bishop, P.R. Nance, A.S. Popel, M. Intaglietta and P.C. Johnson, Effect of erythrocyte aggregation on velocity profiles in venules, Am. J. Physiol. Heart Circ. Physiol. 280 (2001), H222-H236.
19. A. Halupa, M.L. Bailey, K. Huang et al., A novel role for STAT1 in regulating murine erythropoiesis: deletion of STAT1 results in overall reduction of erythroid progenitors and alters their distribution, Blood 15 (2005), 552-561.
20. A. Yoshimura and K. Arai, Physician education: The erythropoietin receptor and signal transduction, Oncologist 1 (1996), 337-339.
21. I. Baciu, L. Ivanof, T. Pavel et al., Erythropoietin binding to the red cell membranes, Physiologie 22 (1985), 227-231.
22. F.P. Barbone, D.L. Johnson, F.X. Farrell et al., New epoetin molecules and novel therapeutic approaches, Nephrol. Dial. Transpl. 14 (1999), 80-84.
23. W. Tong, J. Zhang and H.F. Lodish, Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways, Blood 15 (2005), 4604-4612.
24. C. Brugnara, M.S. Kruskall and R.M. Johnstone, Membrane properties of erythrocytes in subjects undergoing multiple blood donations with or without recombinant erythropoietin, Br. J. Haematol. 84 (1993), 118-130.
25. L. De Franceschi, A. Rivera, M.D. Fleming et al., Evidence for a protective role of the Gardos channel against hemolysis in murine spherocytosis, Blood 15 (2005), 1454-1459.
26. G. Minetti, A. Ciana and C. Balduini, Differential sorting of tyrosine kinases and phosphotyrosine phosphatases acting on band 3 during vesiculation of human erythrocytes, Biochem. J. 377 (2004), 489-497.
27. P. Boivin, Role of the phosphorylation of red blood cell membrane proteins, Biochem. J. 256 (1988), 689-695.
28. C.M. Cohen and P. Gascard, Regulation and post-translational modification of erythrocyte membrane and membraneskeletal proteins, Semin. Hematol. 29 (1992), 244-292.
29. G. Pindur, A. Sander, U.T. Seyfert and F. Jung, The effect of pentoxifylline on the deformability of erythrocytes in erythrocyte concentrates in additive solution, Anasthesiol. Intensivmed. Notfallmed. Schmerzther 36 (2001), S59-S61.
30. F. Jung, C. Mrowietz, D. Rickert, B. Hiebl, J.W. Park and R.P. Franke, The effect of radiographic contrast media on the morphology of human erythrocytes, Clin. Hemorheol. Microcirc. 38 (2008), 1-11.
31. W.A. Anong, T.L. Weis and P.S. Low, Rate of rupture and reattachment of the band 3-ankyrin bridge on the human erythrocyte membrane, Biol. Chem. 281 (2006), 22360-22366.
32. S. Manno, Y. Takakuwa and N. Mohandas, Modulation of erythrocyte membrane mechanical function by protein 4.1 phosphorylation, J. Biol. Chem. 280 (2005), 7581-7587.